NEW ORLEANS -- In an interview at the Society of Nuclear Medicine and Molecular Imaging annual meeting, Phillip Kuo, MD, PhD, of the City of Hope in Duarte, CA, discussed new appropriate use criteria for amyloid and tau PET imaging in Alzheimer’s disease patients.
Video from SNMMI: Phillip Kuo on new Alzheimer’s disease imaging guidelines
Latest in Molecular Imaging
FAPI-PET superior to FDG-PET in liver cancer
April 20, 2026
MITA PET Group rebrands, expands scope to theranostics
April 20, 2026





















